Haploidentical transplants using ex vivo T-cell depletion.
Semin Hematol
; 53(4): 252-256, 2016 10.
Article
em En
| MEDLINE
| ID: mdl-27788763
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. This review will explore how the biological obstacles to HLA-haploidentical (haplo)-HSCT were overcome and how transplant modalities have evolved over time to potentiate the graft-versus-leukemia (GvL) effect in the absence of graft-versus-host disease (GvHD).
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Haplótipos
/
Linfócitos T
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Semin Hematol
Ano de publicação:
2016
Tipo de documento:
Article